Featured Portfolio
The SIMPLE chip addresses several current method bottlenecks and offers simplicity, cost-effectiveness, portability, and quantitative molecular readout, thus paving the way for decentralized molecular tests that can aid rapid medical decisions. Not only will it excel in speed, but it will also offer multi-target panel testing, setting a new standard in this field. Once successfully implemented, this technology will enable swift, decentralized screening at small clinics, pharmacies, and similar locations. It aims to effectively control outbreaks by providing high sensitivity and specificity akin to PCR testing. |
TOP STORIES
PATENTS AND TECHNOLOGY
US court bars Apple Watch imports while patent dispute plays out
by The Guardian in January ‘24
Apple unable to sell Series 9 and Ultra 2 models in US while it challenges decision that watches infringe on patents.
Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss
by Business Wire in January ‘24
Olfactive Biosolutions, a leader in ectopic and chemosensory receptor technology, recently filed a U.S. patent for Protenx, a proprietary line of breakthrough food ingredient formulations.
TOP STORIES
HEALTHCARE TRANSACTIONS
Smith+Nephew completes acquisition of novel cartilage regeneration technology for sports medicine knee repair
by Ortho Spine News in January ‘24
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces that it has completed the acquisition of CartiHeal, developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee. |
EpiVario Announces Acquisition of Acetyl CoA Synthetase 2 (ACSS2) Inhibitor Portfolio from Metabomed LTD
by PR Newswire in January ‘24
“The acquisition of Metabomed’s ACSS2i portfolio provides EpiVario with a proprietary, next generation portfolio of novel, potent and selective small molecule ACSS2 inhibitors,” said Thomas Kim, President and Chief Executive Officer of EpiVario. |
TOP STORIES
PATENTS AND TECHNOLOGY
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
by Yahoo Finance in January ‘24
“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech. |
Shapa Health Breaks Ground with 5th Patent Approval and Trademark Acknowledgment, Pioneering Numberless Scale® AI-Powered Health Solutions in 2024
by PR Newswire in January ‘24
PALO ALTO, Calif., Jan. 10, 2024 /PRNewswire/ — Shapa Health, a leading force in the health technology sector, proudly announces major milestones, marking its 5th patent approval and an official acknowledgment for its trademark application by the United States Patent and Trademark Office (USPTO). |
CURRENT PORTFOLIO AVAILABLE
FOR SALE
AND LICENSE WITH HIGH INTEREST
This system incorporates an active noise control (ANC) device within the structure of the infant incubator. The ANC system is designed to generate sound waves matching the frequency and amplitude of the targeted noises for attenuation. Through calculations executed within microseconds, the system determines the optimal sound wave required at any given moment to minimize the sound pressure level across a wide area. Furthermore, the system facilitates the transmission of a parent’s or caregiver’s voice into the incubator, enabling crucial directed communication with the infant without interference from the incubator walls.
